alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### Ruben LAROTA-FLOREZ; Carmen Rosa Cordova-Pena, Plaintiffs-Appellants, v. GOLDMAN SACHS MORTGAGE COMPANY, A New York Limited Partnership; Litton Loan Servicing, LP; Mortgage Electronic Registration Systems, Incorporated, Defendants-Appellees.

No. 10-1523.

United States Court of Appeals, Fourth Circuit.

Submitted: July 25, 2011.

Decided: July 28, 2011.

Christopher E. Brown, Brown, Brown & Brown, P.C., Alexandria, Virginia, for Appellants. Jason E. Manning, John C. Lynch, Troutman Sanders, LLP, Virginia Beach, Virginia, for Appellees.

Before WILKINSON, KEENAN, and DIAZ, Circuit Judges.

Affirmed by unpublished PER CURIAM opinion.

Unpublished opinions are not binding precedent in this circuit.

*203PER CURIAM:

Ruben Larota-Florez and Carmen Rosa Cordova-Pena appeal the district court’s order granting Defendants’ summary judgment motion on their state law claims for declaratory judgment and quiet title. We have reviewed the record and find no reversible error. Accordingly, we affirm the district court’s order. *See Larota-Florez v. Goldman Sachs Mortg. Co.,*719 F.Supp.2d 636 (E.D.Va.2010); *see also Horvath v. Bank of N.Y., N.A.,*641 F.3d 617 (4th Cir.2011). We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

*AFFIRMED.*
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                         345,000
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                    266,000
<CURRENT-ASSETS>                             3,590,000
<PP&E>                                         596,000
<DEPRECIATION>                                  76,000
<TOTAL-ASSETS>                               4,133,000
<CURRENT-LIABILITIES>                          467,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        27,000
<OTHER-SE>                                   3,639,000
<TOTAL-LIABILITY-AND-EQUITY>                 4,133,000
<SALES>                                          5,000
<TOTAL-REVENUES>                                 5,000
<CGS>                                           55,000
<TOTAL-COSTS>                                1,331,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (1,270,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,270,000)
<DISCONTINUED>                             (1,149,000)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (2,419,000)
<EPS-PRIMARY>                                    (.89)
<EPS-DILUTED>                                    (.89)
        


</TABLE>
**Exhibit 12 (b)****CERTIFICATION PURSUANT TO SECTION 302(A) OF THE SARBANES-OXLEY ACT OF 2002**I, Phil Baker, certify that:1. I have reviewed this annual report on Form 20-F of Lihir Gold Limited (the “company”);2. Based on my knowledge, this report does not contain any untrue statement of a material factor omit tostate a material fact necessary to make the statements made, in light of the circumstances underwhich suchstatements were made, not misleading with respect to the period covered by this report;3. Based on my knowledge, the financial statements, and other financial information included inthis report,fairly present in all material respects the financial condition, results of operations and cashflows of thecompany as of, and for, the periods presented in this report;4. The company’s other certifying officer(s) and I are responsible for establishing andmaintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))andinternal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and15d-15(f)) for thecompany and have: a. Designed such disclosure controls and procedures, or caused suchdisclosure controls andprocedures to be designed under our supervision, to ensure that material informationrelating tothe company, including its consolidated subsidiaries, is made known to us by otherswithin thoseentities, particularly during the period in which this report is being prepared;  b. Designed such internal control over financial reporting, or causedsuch internal control overfinancial reporting to be designed under our supervision, to provide reasonableassuranceregarding the reliability of financial reporting and the preparation offinancial statements forexternal purposes in accordance with generally accepted accounting principles;  c. Evaluated the effectiveness of the company’s disclosure controls andprocedures and presentedin this report our conclusions about the effectiveness of the disclosure controls andprocedures,as of the end of the period covered by this report based on such evaluation; and  d. Disclosed in this report any change in the company’s internal controlover financial reporting thatoccurred during the period covered by the annual report that has materially affected,or isreasonably likely to materially affect, the company’s internal control over financialreporting; and5. The company’s other certifying officer(s) and I have disclosed, based on our most recentevaluation ofinternal control over financial reporting, to the company’s auditors and the audit committee ofthe company’sboard of directors (or persons performing the equivalent functions): a.  All significant deficiencies and material weaknesses in the design or operation ofinternal controlover financial reporting which are reasonably likely to adversely affect the company’sability torecord, process, summarize and report financial information; and  b.  Any fraud, whether or not material, that involves management or other employees whohave asignificant role in the company’s internal control over financial reporting./s/  Phil Baker
# C_2021009EN.01001502.xml

| 11.1.2021 | EN | Official Journal of the European Union | C 9/15 |
| --- | --- | --- | --- |

11.1.2021

EN

Official Journal of the European Union

C 9/15

---

Judgment of the General Court of 28 October 2020 — Target Ventures Group v EUIPO — Target Partners (TARGET VENTURES)

(Case T-273/19) (1)

(EU trade mark - Invalidity proceedings - EU word mark TARGET VENTURES - Absolute ground for invalidity - Bad faith - Article 52(1)(b) of Regulation (EC) No 207/2009 (now Article 59(1)(b) of Regulation (EU) 2017/1001))

(2021/C 9/22)

Language of the case: English

Parties

Applicant: Target Ventures Group Ltd (Road Town, British Virgin Islands) (represented by: T. Dolde and P. Homann, lawyers)

Defendant: European Union Intellectual Property Office (represented by: P. Sipos and V. Ruzek, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Target Partners GmbH (Munich, Germany) (represented by: A. Klett and C. Mikyska, lawyers)

Re:

Action brought against the decision of the Second Board of Appeal of EUIPO of 4 February 2019 (Case R 1684/2017-2), relating to invalidity proceedings between Target Ventures Group and Target Partners.

Operative part of the judgment

The Court:

| 1. | Annuls the decision of the Second Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 4 February 2019 (Case R 1684/2017-2); |
| --- | --- |

1.

Annuls the decision of the Second Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 4 February 2019 (Case R 1684/2017-2);

| 2. | Orders EUIPO to bear its own costs and to pay those incurred by Target Ventures Group Ltd, including those which the latter party incurred before the Board of Appeal; |
| --- | --- |

2.

Orders EUIPO to bear its own costs and to pay those incurred by Target Ventures Group Ltd, including those which the latter party incurred before the Board of Appeal;

| 3. | Orders Target Partners GmbH to bear its own costs. |
| --- | --- |

3.

Orders Target Partners GmbH to bear its own costs.

---

(1)  OJ C 220, 1.7.2019.

---
# Official Journal C 334/2019

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 334 |
| | |
| English edition | Information and Notices | Volume 624 October 2019 |

ISSN 1977-091X

Official Journal

of the European Union

C 334

English edition

Information and Notices

Volume 624 October 2019

---

| Contents | page |
| --- | --- |
| | IV   Notices |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2019/C 334/01 | Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2019 to 31 August 2019  (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council) | 1 |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| 2019/C 334/02 | Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2019 to 31 August 2019  (Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC) | 17 |

Contents

page

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2019/C 334/01

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2019 to 31 August 2019  (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

1

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

2019/C 334/02

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2019 to 31 August 2019  (Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

17

---

| EN | |
| --- | --- |

EN
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Federal Deposit Insurance Corporation

# FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT:

The previously announced meeting agenda of the Board of Directors, published at 86 FR 37752, has changed.

# PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: 

Tuesday, July 20, 2021, at 10:00 a.m.

# CHANGES IN THE MEETING:

Pursuant to the provisions of the “Government in the Sunshine Act” (5 U.S.C. 552b), notice is hereby given that the following matter will be deferred from the Summary Agenda at the open meeting of the Board of Directors of the Federal Deposit Insurance Corporation scheduled to be held at 10:00 a.m. on July 20, 2021, via a Webcast live on the internet:

*Memorandum and resolution re:*                         Notice of Proposed Rulemaking on Revisions to Standardized Approach for Calculating the Exposure Amount of Derivative Contracts.                    

# CONTACT PERSON FOR MORE INFORMATION:

Requests for further information concerning the meeting may be directed to Debra A. Decker, Deputy Executive Secretary of the Corporation, at (202) 898-8748.

Federal Deposit Insurance Corporation.

Dated at Washington, DC, on July 19, 2021.

James P. Sheesley,

Assistant Executive Secretary.

[FR Doc. 2021-15672 Filed 7-20-21; 11:15 am]

BILLING CODE 6714-01-P
<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE FORM
10-QSB REPORT OF OVM INTERNATIONAL HOLDING CORP. FOR THE QUARTERLY PERIOD ENDED
MARCH 31, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH REPORT.
</LEGEND>
<MULTIPLIER>                                         1,000   
<CURRENCY>                                   RENMINBI YUAN   
                                           
<S>                             <C>
<PERIOD-TYPE>                    3-MOS
<FISCAL-YEAR-END>                              DEC-31-1999  
<PERIOD-START>                                 JAN-01-1999  
<PERIOD-END>                                   MAR-31-1999  
<EXCHANGE-RATE>                                       8.28  
<CASH>                                              20,637  
<SECURITIES>                                             0  
<RECEIVABLES>                                       57,896  
<ALLOWANCES>                                         8,243  
<INVENTORY>                                         49,653  
<CURRENT-ASSETS>                                   160,393  
<PP&E>                                              31,014  
<DEPRECIATION>                                       9,572  
<TOTAL-ASSETS>                                     214,523  
<CURRENT-LIABILITIES>                              115,032  
<BONDS>                                                  0  
<PREFERRED-MANDATORY>                                    0  
<PREFERRED>                                              0  
<COMMON>                                                10  
<OTHER-SE>                                          62,416  
<TOTAL-LIABILITY-AND-EQUITY>                       214,523  
<SALES>                                             35,783  
<TOTAL-REVENUES>                                    36,265  
<CGS>                                               19,163  
<TOTAL-COSTS>                                       30,804  
<OTHER-EXPENSES>                                         0  
<LOSS-PROVISION>                                         0  
<INTEREST-EXPENSE>                                     943  
<INCOME-PRETAX>                                      4,518  
<INCOME-TAX>                                           744  
<INCOME-CONTINUING>                                  3,774  
<DISCONTINUED>                                           0  
<EXTRAORDINARY>                                          0  
<CHANGES>                                                0  
<NET-INCOME>                                         2,549  
<EPS-PRIMARY>                                         0.21  
<EPS-DILUTED>                                         0.21  
                                              

</TABLE>
Exhibit 10.1

Confidential

LOGO

Interoffice Memorandum



|      |  |                                                          
|----- |  | ---------------------------------------------------------
|To:   |  | Personnel File                                           
|      | 
|From: |  | Timothy M. Shannon, EVP & Chief Medical Officer          
|      | 
|Date: |  | January 25, 2006                                         
|      | 
|Re:   |  | Amendment to Employment Agreement dated September 9, 2002



---

I, Timothy M. Shannon, (the Executive) signed an Employment Agreement (the Agreement) with my employer, CuraGen Corporation (the Company), on or about September 9, 2002, and subsequently signed an
Addendum to the Agreement on October 31, 2003. Exhibit A, Item 1) of the original Agreement provides that the Executives initial base salary shall be subject to increases by the Board of Directors, which shall review the salary
periodically. Therefore, pursuant to the minutes of the January 26, 2006, Meeting of the Compensation Committee of the Board of Directors, the Executives 2006 base salary will be adjusted to $325,000 per year, payable in bi-weekly
installments.

Unless explicitly changed in the Addendum dated October 31, 2003, all other terms of the original Agreement shall remain in full force
and effect.



|                  
|------------------
|Timothy M. Shannon
|                  
|                  
|Patrick J. Zenner
Exhibit 32.1

CERTIFICATION PURSUANT TO 
18 U.S.C. SECTION 1350, 
AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Synovics Pharmaceuticals, Inc. (the Company) for the quarterly period ended April 30, 2009 filed with the Securities and
Exchange Commission (the Report), I, Jyotindra Gange, Principal Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

|(1) | The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and                                                                                                                                     
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   
|(2) | The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and consolidated results of operations of the Company for the
periods presented.
|   

Dated: June 22, 2009

|    |                                
|--- | -------------------------------
|By: | /s/
        Jyotindra Gange    
|    | Jyotindra Gange                
|    | Principal Executive
    Officer







This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

A signed original of this written statement required by Section 906 has been provided to Synovics Pharmaceuticals, Inc. and will be retained by Synovics Pharmaceuticals, Inc. and furnished to the Securities and Exchange
Commission or its staff upon request.

---
# C_2021228EN.01002901.xml

| 14.6.2021 | EN | Official Journal of the European Union | C 228/29 |
| --- | --- | --- | --- |

14.6.2021

EN

Official Journal of the European Union

C 228/29

---

Order of the General Court of 9 April 2021 — Laroni v Parliament

(Case T-415/19) (1)

(Law governing the institutions - Single statute for Members of the European Parliament - Members of the European Parliament elected for Italian constituencies - Adoption by the Ufficio di Presidenza della Camera dei deputati (Office of the President of the Italian Chamber of Deputies, Italy) of Resolution No 14/2018, on pensions - Change in the amount of pensions for Members of the Italian national Parliament - Corresponding change, by the European Parliament, in the amount of pensions for certain former Members of the European Parliament elected in Italy - Death of the applicant - Proceedings not resumed by the successors - No need to adjudicate)

(2021/C 228/39)

Language of the case: Italian

Parties

Applicant: Nereo Laroni (Venice, Italy) (represented by: M. Merola, lawyer)

Defendant: European Parliament (represented by: S. Seyr and S. Alves, acting as Agents)

Re:

Application under Article 263 TFEU for annulment of the note of 11 April 2019 of the Parliament concerning adjustment of the amount of the pension which the applicant receives following the entry into force on 1 January 2019 of Resolution No 14/2018 of the Ufficio di Presidenza della Camera dei deputati.

Operative part of the order

| 1. | There is no longer any need to adjudicate on the present action. |
| --- | --- |

1.

There is no longer any need to adjudicate on the present action.

| 2. | Each party shall bear its own costs. |
| --- | --- |

2.

Each party shall bear its own costs.

---

(1)  OJ C 295, 2.9.2019.

---
Exhibit 10(xii)

                 2010 Schedule of Executive Officer Compensation
                 -----------------------------------------------


   On December 17, 2009, the Compensation Committee approved the following 2010
   salaries for the named executive officers of the Company:

<TABLE>
<CAPTION>
<S>                                                                                <C>

   Name and Principal Position                                                     Salary
   ---------------------------                                                     ------

   Mark D. Bradford, President, CEO and Director                                   $225,000

   Gordon M. Dyott, Executive Vice President, Chief Financial Officer              $147,750

   Christopher G. Tietz, Senior Vice President, Chief Credit Officer               $145,250

   R. Scott Walters, Senior Vice President, Wealth Management Group                $123,500

   J. Scot Davidson, Senior Vice President, Retail Banking                         $106,986
</TABLE>

Monthly and Annual Variable Incentive Compensation. The named executive officers
are not eligible to participate in the monthly or annual variable incentive
compensation program in 2010.

During 2010 Mark Bradford will also receive from the Company certain perquisites
with a total value estimated at approximately $13,000. These perquisites consist
of a car allowance and social club memberships. While the other executive
officers enjoy certain perquisites, such perquisites are not anticipated to
exceed $10,000 and therefore would not be required to be disclosed by applicable
rules of the Securities and Exchange Commission.


Stock Option Grants. On December 17, 2009, the Compensation Committee approved
the award of stock option grants to the following named executive officers in
the amounts set forth next to their names:

                Mark D. Bradford                     10,000 shares
                Gordon M. Dyott                       5,000 shares
                Christopher G. Tietz                  5,000 shares
                R. Scott Walters                      5,000 shares
                J. Scot Davidson                      5,000 shares

The options vest in three years and the option price is based on the closing
price on December 16, 2009 which was $6.00 per share.